ZBH - CapitalGainsReport Sector Spotlight: Orthobiologics Watchlist (ORHB ZBH GMED SYK)
(NewsDirect)
Orthobiologics represents a dynamicfield within healthcare where the body's natural healingmechanisms address osteoarthritis and enhance recovery from tendon andligament injuries. These therapies signify a significant evolution inmedical treatment, offering promising solutions for patientsworldwide.
The global orthobiologicsmarket is experiencing substantial growth, with projections exceedingUS$6.5 billion by 2022 and maintaining a steady CAGR of 5.9% until2030. Various factors fuel this growth, including demographic shiftswith an aging population, an increase in spine abnormalities, andadvancements in stem cell research. Companies actively driveinnovation through developing bone graft substitutes and minimallyinvasive procedures, expanding the market's reach andimpact.
Let's explore theprofiles of four key players actively driving innovation and shapingthe future of orthobiologics:
HippoFi (OTC: ORHB) is a company that is expanding itspresence in the healthcare industry, fueled by cutting-edge technologyand an innovative approach to medicine. The company's unwaveringdedication to delivering groundbreaking healthcare solutions isevident through its focused efforts on pioneering first-to-marketsolutions across the multibillion-dollar biotech, fintech, and AIsectors.
At the heart ofHippoFi's success lies its suite of proprietary technologiesmeticulously crafted to address critical medical needs and enhancepatient outcomes. Anchoring its operations is PUR Biologics, thecompany's regenerative therapeutics division, committed todeveloping and deploying scalable biological solutions within the$1.37 trillion biotechnology market.
HippoFi's portfolio encompasses advanced allografts anddemineralized extracellular matrices (d-ECM), representinggroundbreaking advancements in tissue regeneration and repair. Theseinnovative solutions offer a holistic approach to healing, aiming torestore function and mobility to patients grappling with degenerativeconditions.
Moreover, HippoFi'ssynthetic bone-forming solutions and cellular-derived tissues signifysignificant milestones in orthopedic care. By harnessing the power ofregenerative stem cells and growth factors, HippoFi is at theforefront of pioneering next-generation therapeutics for treatingosteoarthritis and facilitating cartilage regeneration.
What sets HippoFi apart is its commitmentto personalized medicine, leveraging biotech and AI technologies todevelop tailored treatments for individual patient needs. Throughstrategic partnerships with industry leaders such as ZIMMER BIOMET andHoag Hospital Newport Beach, HippoFi is spearheading innovation inspine care solutions, revolutionizing the delivery of spinalbiologics.
The recent acquisition ofactiveOrb technology further solidifies HippoFi's position as aleader in the regenerative therapeutics market. This cutting-edgetechnology enhances HippoFi's capabilities in bone-growthsolutions, reaffirming its commitment to advancing healthcaretechnologies and solutions.
OnJanuary 23, 2024, HippoFi's (OTC: ORHB) biotechnology arm, PURBiologics, proudly announced Scott Bauccio as its new Head of Sales.Leveraging his 20 years of sales management and extensive network ofindustry-leading professionals, Bauccio is expanding the company'ssales and distribution channels. Already securing two new products,PURamnio (available now) and PURpeptide (launching within 30 days),Bauccio's appointment underscores HippoFi's strategic focus ongrowth and market expansion.
"Weare excited to welcome Scott to our team. His proven success indriving growth and remarkable ability to establish a strong marketpresence are perfectly aligned with our objectives," says RyanFernan, Head of PUR Biologics.
CJWiggins, Executive Chairman and CEO of HippoFi, shared,"Scott's appointment is a tactical move to strengthen ourleadership team at a pivotal time in our sales growth. His industryexpertise and market insights are invaluable in our continuous pursuitof innovation and excellence in the biologic sector."
During his tenure as the Vice President ofSales & Business Development at Biogennix, Bauccio successfullyestablished the company's ortho-spine biologic sales anddistribution channels throughout the United States. His appointmentreflects the first of several strategic actions HippoFi will take in2024 to further their commitment to leading the industry as theauthority in regenerative biologics.
In summary, HippoFi's proprietary technologies, strategicpartnerships, and exponential growth trajectory position it as atrailblazer in the healthcare sector. By harnessing the power ofbiotech and AI, HippoFi is spearheading transformative treatments thathave the potential to revolutionize patient care and drive significantvalue for shareholders.
ZimmerBiomet Holdings, Inc. (NYSE: ZBH) stands at the forefront ofmedical technology, specializing in orthopedic reconstructiveproducts. With over 90 years of experience, the company continues todrive innovation and shape the future of orthopedic care.
In the third quarter of 2023, ZimmerBiomet reported impressive financial results, with a 5.0% increase innet sales, reaching $1.754 billion. These figures underscore thecompany's financial strength and resilience in a rapidly evolvinghealthcare landscape.
Key to ZimmerBiomet's success is its commitment to strategic leadershipchanges. The appointment of CEO Ivan Tornos reflects a dedication toinnovation and commercial execution, positioning the company forcontinued growth. Further leadership updates, including the expandedrole of CFO Suketu Upadhyay, demonstrate Zimmer Biomet's proactiveapproach to driving excellence in orthopedic healthcare.
Zimmer Biomet's commitment toinnovation is demonstrated by milestones such as enrolling 100,000patients in the MyMobility care management system. This platformintegrates automation, data, and insights to enhance the orthopedicpatient experience, underscoring Zimmer Biomet's commitment toimproving outcomes and patient satisfaction.
Recognized for its Environmental, Social,and Governance (ESG) initiatives, Zimmer Biomet has earned accoladessuch as inclusion on the Newsweek America's Greenest Companies2024 list and the Sustainability Magazine Top 10: SustainableHealthcare Device Companies.
Furthermore, Zimmer Biomet's commitment to delivering valueto shareholders is evident in its approval of a quarterly cashdividend of $0.24 per share for Q4 2023, reinforcing its dedication toshareholder returns and long-term sustainability.
Globus Medical, Inc. (NYSE: GMED) has been a pioneering force in medical technology since its foundingin 2003. The company's core mission is to develop innovativeproducts that empower surgeons to enhance healing in patients withmusculoskeletal disorders.
GlobusMedical has a market capitalization of $6.81 billion and is poised forgrowth, owing primarily to the success of its U.S. spine and traumaportfolios. Despite encountering macroeconomic challenges affectingprofit margins, the company has experienced a noteworthy 31.2% stockincrease over the past year.
With along-term estimated earnings growth rate of 11.5%, slightly below theindustry average of 13.3%, GMED has consistently outperformed earningsestimates, delivering an average surprise of 5.44% in the last fourquarters.
In terms of strategicupsides, GMED reported a 10.7% increase in musculoskeletal revenues inthe third quarter. This success is attributed to the launch ofinnovative products like REFLECT, MARVEL, and Ossifuse, withexpectations of a robust series of product launches throughout theMusculoskeletal portfolio in 2024.
The company continues to prioritize product development, asevidenced by the September 2023 launch of the Precice Bone Transportsystem, Hydrone, and the Strato trauma wiring system. Surgeons canexpect to have access to a growing number of options, including a3D-printed interbody portfolio, cervical discs, robotic prone andlateral systems, EGPS E3D, neuromonitoring solutions, retractors, andlimb-lengthening products.
Financially resilient, GMED ended Q3 2023 with $468.9 million incash and short-term marketable securities, showcasing strongliquidity, solvency, and a debt-free balance sheet.
In recent developments, Globus Medical,Inc. announced preliminary unaudited sales results for the fourthquarter and full year ending December 31, 2023. The companyanticipates fourth-quarter 2023 sales of approximately $615.5 million,an increase of 124.2 percent over the fourth quarter 2022 on anas-reported basis. Full-year 2023 sales are expected to beapproximately $1.567 billion, an increase of 53.2 percent over theprior year on an as-reported basis.
Dan Scavilla, president and CEO of Globus Medical, highlightedthe monumental year, including the completion of a merger withNuVasive to create the most innovative technology company in the spinemarket. Revenue for the full year and fourth quarter of 2023 set newrecords, indicating significant progress in U.S. Spine and EnablingTechnologies.
Looking ahead, GlobusMedical is focused on delivering product innovation, superior customerservice, and operational excellence to advance patient care. Thecompany's trajectory of product launches and advancementspositions it for sustained growth and impact in the medical deviceindustry.
Keith Pfeil, CFO of GlobusMedical, emphasized the company's strong finish in Q4 and itsoverall full-year performance, outlining objectives for 2024,including sales growth, continued merger integration activities, andrealizing synergy capture. The company established a full-year 2024revenue guidance range of $2.450 billion to $2.475 billion and a fullydiluted non-GAAP earnings per share range of $2.68 to $2.70.
Stryker Corporation (NYSE: SYK) isa leader in medical technology with a global focus, committed toimproving healthcare outcomes across the board. With an extensiveportfolio spanning medical and surgical, neurotechnology, orthopedics,and spine, the company impacts over 130 million patientsannually.
The company, headquarteredin Kalamazoo, Michigan, specializes in MedSurg, neurotechnology,orthopedics, and spine solutions. Stryker's commitment toinnovation and improving healthcare outcomes is evident in itsextensive product portfolio and continuous advancements inspine-related technology.
Under theleadership of Robbie Robinson, President of the Spine division,Stryker's Spine business has experienced significant growth. Theintroduction of innovative products like the Q Guidance System withSpine Guidance Software has been recognized with industry awards,demonstrating Stryker's dedication to surgical spine planning andnavigation.
Key products like theMonterey AL Interbody System, incorporating Tritanium In-GrowthTechnology, and the OmniCurve curved balloon system further exemplifyStryker's commitment to enhancing surgical capabilities andpatient outcomes.
In January 2024,Stryker announced its fourth-quarter earnings, reporting profits of$1.14 billion. Earnings per share were $2.98, with adjusted earningsof $3.46 per share, exceeding Wall Street expectations. Thecompany's revenue for the quarter stood at $5.82 billion,surpassing analysts' forecasts.
For the full year 2023, Stryker reported a profit of $3.17billion, or $8.25 per share, with total revenue reaching $20.5billion. Looking ahead, Stryker expects full-year earnings in therange of $11.70 to $12 per share, demonstrating confidence in itsfuture growth trajectory.
Stryker's exceptional financial performance, coupled withits continuous innovation in spine-related technology, positions thecompany as a major player in the medical device sector and underscoresits potential for sustained success.
Disclaimers: The PrivateSecurities Litigation Reform Act of 1995 provides investors a safeharbor in regard to forward-looking statements. Any statements thatexpress or involve discussions with respect to predictions,expectations, beliefs, plans, projections, assumptions, objectives,goals, or assumptions of future events or performance are notstatements of historical fact may be forward looking statements.Forward looking statements are based on expectations, estimates, andprojections at the time the statements are made that involve a numberof risks and uncertainties which could cause actual results or eventsto differ materially from those presently anticipated. Forward lookingstatements in this action may be identified through use of words suchas projects, foresee, expects, will, anticipates, estimates, believes,understands, or that by statements, indicating certain actions "es; may, could or might occur Understand there is no guaranteepast performance is indicative of future results. Investing inmicro-cap or growth securities is highly speculative and carries anextremely high degree of risk. It is possible that an investor'sinvestment may be lost or due to the speculative nature of thecompanies profiled. Capital Gains Report (CGR), owned by RazorPitchInc., is responsible for the production and distribution of thiscontent. CGR is not operated by a licensed broker, a dealer, or aregistered investment advisor. It should be expressly understood thatunder no circumstances does any information published herein representa recommendation to buy or sell a security. CGR has been retained byHippoFi Inc to produce and distribute this content. As part of thatcontent, readers, subscribers, and webs are expected to read the fulldisclaimers and financial disclosure statement that can be found onour website capitalgainsreport.com All content in this article isinformation of a general nature and does not address the circumstancesof any particular individual or entity. Nothing in this articleconstitutes professional and/or financial advice, nor does anyinformation in the article constitute a comprehensive or completestatement of the matters discussed or the law relating thereto. CGR isnot a fiduciary by virtue of any persons use of or access to thiscontent.
Contact Details
Mark McKelvie
+1585-301-7700
CompanyWebsite
Copyright (c) 2024 TheNewswire - All rights reserved.